This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

A Preliminary Report

F. D. HENDRICKS, M.D.; A. B. GREAVES, M.D.; S. OLANSKY, M.D.; S. R. TAGGART, M.D.; C. N. LEWIS, M.D.; G. S. LANDMAN, M.D.; G. R. MacDONALD, M.D.; HENRY WELCH, Ph.D.

J Am Med Assoc. 1950;143(1):4-5.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The discovery of terramycin, an antibiotic produced by Streptomyces rimosus, has only recently been reported,¹ yet an extensive clinical program is already under way to evaluate this new addition to the group of drugs useful in the treatment of infectious diseases. In vitro and in vivo studies indicate that terramycin has a wide bacterial spectrum² effective against both grampositive and gram-negative bacteria, certain of the rickettsias and viruses. It appears in many respects to be comparable to aureomycin in its antimicrobial activity. The drug is readily absorbed from the gastro-intestinal tract and produces significant and continuous blood concentrations when 250 mg. are given orally every six hours.^2a It is readily excreted by the kidneys and appears in the urine in an active state. The amount of terramycin excreted depends on the dose and varies from 10 to 35 per cent of the total amount of drug ingested. . . . [Full Text PDF of this Article]

Author Affiliations
Washington, D. C.

From the District of Columbia Health Department and the Federal Security Agency, Food and Drug Administration.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?